2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Melanoma
76
Neoplasms
29
Thyroid Neoplasms
11
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
10
Thyroid Carcinoma, Anaplastic
9
Glioma
9
Brain Neoplasms
9
Multiple Myeloma
7
Colorectal Neoplasms
7
Skin Neoplasms
6
Hematologic Neoplasms
6
Thyroid Cancer, Papillary
4
Ameloblastoma
4
Lung Neoplasms
3
Histiocytosis, Langerhans-Cell
3
Glioblastoma
3
Astrocytoma
3
Rectal Neoplasms
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neurofibroma, Plexiform
2
Neurocytoma
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Ganglioneuroma
2
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
dabrafenib
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled